Blood Donor CVD 9000

Phase 4TerminatedNCT03724357

University of Maryland, Baltimore3 enrolled

Overview

This is an open-label, non-randomized study. Volunteers will be vaccinated with the oral cholera vaccine, Vaxchora. Vaxchora has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechanisms that can be elicited systemically and may be applicable to other enteric pathogens.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Cholera Vaccination

Interventions

VaxchoraDRUG

One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Age 18 years to 64 years at the time of enrollment * 2\. Good general health as determined by a screening evaluation within 28 days before blood donation or vaccination * 3\. Provides written informed consent prior to initiation of any study procedures Exclusion Criteria: * 1\. History of any of the following medical conditions: * Diabetes * Cancer in past 5 years (except for basal cell carcinoma of the skin and cervical carcinoma in situ) * Heart disease (e.g., hospitalization for a heart attack, coronary artery bypass graft, arrhythmia, or syncope, within past 5 years. Current symptoms of heart disease, such as dyspnea, angina, or orthopnea) * Recurrent infections (e.g., more than 3 hospitalizations for invasive bacterial infections such as pneumonia or meningitis) * Current drug or alcohol abuse * Active ulcer disease or ongoing intestinal condition * Treatment for anemia in last 6 months * Treatment with anti-malarial drugs within ten days prior to study vaccination * Treatment with antibiotics within 14 days prior to study vaccination * Immunodeficiency or immunosuppression from illness or treatment * 2\. Close contact within 7 days following study vaccination with a person who has an immunodeficiency or immunosuppression from illness or treatment * 3\. History of cholera infection or cholera vaccination * 4\. Any of the following complete blood count (CBC) abnormalities during screening: * white blood cells (WBC) \<0.81 x lower limit of normal (LLN) or \> 1.09 x upper limit of normal (ULN) * Hemoglobin \<0.91 x LLN or \>1.18 x ULN (women) or \<0.92 x LLN or \>1.18 x ULN (men) * Platelet count \<0.8 x LLN or \> 1.2 x ULN * 5\. Any of the following laboratory abnormalities during screening: * serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) \>1.5 times normal * Positive serology for HIV antibody * 6\. Poor peripheral venous access for blood donation * 7\. Other condition that the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or interfere with the scientific integrity of study * 8\. Positive urine pregnancy test (HCG) on the day of vaccination

Locations (1)

University of Maryland, Baltimore, Center for Vaccine Development and Global Health

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Change in the Absolute Percentage of Positive CD4+ CD25+/OX40+ T Cells

Change in absolute percentage of positive CD4+ T cell (CD25+/OX40+) responses. T cell responses were defined by changes in T cell activation markers as compared to pre-immunization levels following ex vivo stimulation with cholera specific antigens. Cells were collected at baseline and on day 3 after immunization with the CVD103-HgR cholera vaccine.

Time frame: Baseline and Day 3

Change in Absolute Percentage of Positive CD4+ CD25+/OX40+ T Cells

Change in absolute percentage of positive CD4+ T cell (CD25+/OX40+) responses. T cell responses were defined by changes in T cell activation markers as compared to pre-immunization levels following ex vivo stimulation with cholera specific antigens. Cells were collected at baseline and on day 5 after immunization with the CVD103-HgR cholera vaccine.

Time frame: Baseline and Day 5

Change in Absolute Percentage of Positive CD4+ CD25+/OX40+ T Cells

Change in absolute percentage of positive CD4+ T cell (CD25+/OX40+) responses. T cell responses were defined by changes in T cell activation markers as compared to pre-immunization levels following ex vivo stimulation with cholera specific antigens. Cells were collected at baseline and on day 8 after immunization with the CVD103-HgR cholera vaccine.

Time frame: Baseline and Day 8

Change in Absolute Percentage of Positive CD4+ CD25+/OX40+ T Cells

Change in absolute percentage of positive CD4+ T cell (CD25+/OX40+) responses. T cell responses were defined by changes in T cell activation markers as compared to pre-immunization levels following ex vivo stimulation with cholera specific antigens. Cells were collected at baseline and on day 10 after immunization with the CVD103-HgR cholera vaccine.

Time frame: Baseline and Day 10

Change in Absolute Percentage of Positive CD4+ CD25+/OX40+ T Cells

Change in absolute percentage of positive CD4+ T cell (CD25+/OX40+) responses. T cell responses were defined by changes in T cell activation markers as compared to pre-immunization levels following ex vivo stimulation with cholera specific antigens. Cells were collected at baseline and on day 15 after immunization with the CVD103-HgR cholera vaccine.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.